The total prevalent population of Nontuberculous Mycobacteria Infection in 7MM is expected to be 3,95,429 by 2030.
The United States accounts for approximately 49% of the total prevalent population in 7MM.
The therapeutic market of Nontuberculous Mycobacteria Infection in 7MM is expected to grow at a CAGR of 6.6% during the study period.
The key players in the Nontuberculous Mycobacteria Infection market include Insmed Inc., RedHill Biopharma, Novoteris, Savara Inc, Beyond Air and others.
For more information visit:
https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market